Inovio unit gets approval in South Korea to test avian flu vaccine

03/2/2010 | American City Business Journals

Inovio Biomedical said regulators in South Korea granted its affiliate, VGX International, approval to begin a first-stage trial of an experimental DNA vaccine against H5N1 flu. Inovio said it plans to start testing the vaccine in the U.S. later this year as it works on a DNA-based universal flu vaccine.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regulatory Compliance Specialist
MJHS
Brooklyn, NY
Director of Utilization Management
Meridian Health Plan
Chicago, IL
Senior Manager, Healthcare Reform
Avalere Health
Washington, DC
Regulatory Senior Managing/Principal Engineer/Scientist
Exponent
Menlo Park, CA
Director of Claims
Meridian Health Plan
Detroit, MI